

RECONCILIATION OF SHARE CAPITAL AUDIT FOR THE QUARTER ENDED 31ST MARCH, 2023*(Regulation 76 of SEBI (Depository and Participant) Regulations, 2018)*

1.	For the quarter ended	March 31, 2023					
2.	ISIN	INE03QK01018					
3.	Face Value	Re. 1.00/- each					
4.	Name of the Company	SUVEN PHARMACEUTICALS LIMITED					
5.	Registered Office Address	# 8-2-334, SDE Serene Chambers 3rd Floor, Avenue 7, Road No. 5 Banjara Hills, Hyderabad – 500 034					
6.	Correspondence Address	Same as above					
7.	Telephone & Fax No.	Ph: 040 – 23549414/3311 Fax 040 – 23541152					
8.	Email Address	<u>khrao@suvanpharm.com</u>					
9.	Names of the Stock exchanges where the Company's Securities are listed.	BSE Limited National Stock Exchange of India Ltd					
			Number of shares	% of Total Issued Capital			
10.	Issued Capital		25,45,64,956	100.00%			
11.	Listed Capital (exchange wise) <i>(as per Company Records)</i>		25,45,64,956–NSE 25,45,64,956–BSE	100.00% 100.00%			
12.	Held in dematerialized form in CDSL		1,32,42,594	5.20%			
13.	Held in dematerialized form in NSDL		24,07,51,996	94.58%			
14.	Physical		5,70,366	0.22%			
15.	Total No. of shares (12+13+14)		25,45,64,956	100.00%			
16.	Reasons for difference if any between (10&11, 10& 15, 11 & 15)			NIL			
17.	Certifying the details of changes in sharecapital during the quarter under consideration as per Table Below						
	Particulars*	No. of Shares	Applied or not applied for listing	Listed on Exchanges (specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Approval pending for stock exchange (Specify names)
	NIL	NIL	NIL	NIL	NIL	NIL	NIL

*Rights, Bonus, Pref. Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital reduction, forfeiture, any other (Specify)

**OFFICE :**

Plot No. 143, Flat No. 301, SV's Kausalya Complex, Rajeev Nagar, Hyderabad - 45.

